U.S. markets open in 6 hours 12 minutes
  • S&P Futures

    4,245.25
    +9.00 (+0.21%)
     
  • Dow Futures

    33,946.00
    +111.00 (+0.33%)
     
  • Nasdaq Futures

    14,292.00
    +33.75 (+0.24%)
     
  • Russell 2000 Futures

    2,298.70
    +6.20 (+0.27%)
     
  • Crude Oil

    73.08
    +0.02 (+0.03%)
     
  • Gold

    1,781.70
    +4.30 (+0.24%)
     
  • Silver

    25.97
    +0.11 (+0.42%)
     
  • EUR/USD

    1.1920
    -0.0023 (-0.19%)
     
  • 10-Yr Bond

    1.4720
    0.0000 (0.00%)
     
  • Vix

    16.66
    -1.23 (-6.88%)
     
  • GBP/USD

    1.3966
    +0.0018 (+0.13%)
     
  • USD/JPY

    110.9050
    +0.2700 (+0.24%)
     
  • BTC-USD

    33,945.16
    +1,230.96 (+3.76%)
     
  • CMC Crypto 200

    814.10
    +19.77 (+2.49%)
     
  • FTSE 100

    7,104.35
    +14.34 (+0.20%)
     
  • Nikkei 225

    28,874.89
    -9.24 (-0.03%)
     

Aldeyra Therapeutics to Present at the 10th Annual SVB Leerink Global Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will present at the 10th Annual SVB Leerink Global Healthcare Conference at 3:40 p.m. ET Friday, February 26, 2021.

A live webcast of the presentation will be available on the investor relations page of the company’s corporate website at https://ir.aldeyra.com/. After the live webcast, the event will remain archived on the Aldeyra Therapeutics website for 90 days.

About Aldeyra Therapeutics, Inc.
Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead investigational compounds, reproxalap and ADX-629, target RASP (reactive aldehyde species), which are elevated in ocular and systemic inflammatory disease and result in cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company’s clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in development for COVID-19 and ovarian cancer. For more information, visit https://www.aldeyra.com/ and follow us on LinkedIn, Facebook, and Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210218005125/en/

Contacts

Corporate Contact:
Joshua Reed
Aldeyra Therapeutics, Inc.
Tel: 781-761-4904 ext. 218
jreed@aldeyra.com

Investor & Media Contact:
Scott Solomon
Sharon Merrill Associates, Inc.
Tel: 617-542-5300
ALDX@investorrelations.com